Chelsea Therapeutics International, Ltd. (CHTP) announced today that a preliminary analysis of its dose-ranging exploratory Phase II trial of CH-4051 (a non-metabolized antifolate for the treatment of rheumatoid arthritis) did not demonstrate superior efficacy to methotrexate in the dose range evaluated. Dr. Simon Pedder, President and CEO of Chelsea Therapeutics, commented: Results of this study […]